Live tape
Top 8, mentions 7d11,476SPCX2,435 mentions▲ +0.08GOOGL1,989 mentions▲ +0.02META1,794 mentions▲ +0.04TSLA1,707 mentions▲ +0.05NFLX973 mentions▲ +0.03QQQ888 mentions▲ +0.04AMZN848 mentions▲ +0.06NVDA842 mentions▲ +0.06

Equity · Healthcare

ALLO

NASDAQ

Allogene Therapeutics (ALLO)

$1.24 −0.80% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Oct 23, 2026

Reddit mentioned ALLO 5 times in the 30 days to 26 October 2026, across 4 of the communities we track. All of them were scored for sentiment: 80% read bullish, 0% bearish and 20% neither. Reddit data updated 26 October 2026.

Price · Chart
63 sessions
$2.5 $1.0 28 Jul 23 Oct

The line runs $1.66 on 28 July through $1.24 on 23 October, on a scale from $1.0 to $2.5. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 63 sessions, 28 Jul – 23 Oct 2026
Market cap $428.4M
52-week range $1.05 – $3.11
Avg volume 310.9K
Mentions · 30d 5
Net sentiment +0.14

as of Oct 23, 2026

Allogene Therapeutics (ALLO) · crowd attention × price

Share ↗
Post on X Share on Reddit Share on LinkedIn
5 mentions

Day22 Oct 2026

MENTIONS10–2 / day
PRICE$1.25$1.2–$1.8
ALLO over the last 30 days, plotting daily Reddit mentions as bars, left-hand scale; the daily closing price as a line on its own right-hand scale, solid across consecutive trading days, held flat and diagonally hatched over days the market was closed, diagonally hatched over days we hold no close for.per day012usd$1.2$1.4$1.6$1.827 Sep4 Oct12 Oct19 Oct26 Oct
ALLO over the last 30 days, plotting daily Reddit mentions as bars, left-hand scale; the daily closing price as a line on its own right-hand scale, solid across consecutive trading days, held flat and diagonally hatched over days the market was closed, diagonally hatched over days we hold no close for.27 Sep12 Oct26 Oct
The Distributed Sentinel 26 Oct 2026

ALLO's busiest day for Reddit mentions was also its highest close of the window — 1 mentions and $1.63 on 28 September

This chart in words

The chart plots daily Reddit mentions of ALLO over the 30 days to 26 October 2026: 5 in total, busiest on 28 September with 1, and 1 on the last day counted. Across this window the close ran between $1.24 on 23 October and $1.63 on 28 September. The line is the daily close over the same window: $1.63 on 28 September, $1.24 on 23 October. Of those days, 20 were trading sessions and the other 10 are hatched on the chart. On 8 of them no session took place, and the last close before it is carried forward rather than plotted; on 1 of them no session took place, and this window holds no earlier close to carry forward; on 1 of them we hold no close at all, which is a gap in our own record rather than a closure we can prove.

Allogene Therapeutics (ALLO) on Reddit · 30d

n = 5 scored · Method

In the 30 days to 26 Oct 2026, Allogene Therapeutics drew 5 Reddit mentions in the finance subreddits we track, 5 of them scored for sentiment.

ALLO

80% bullish

Overall market sentiment

54% bullish

ALLO reads 26 points more bullish than overall market sentiment. Same measure; same 30-day window.

Where ALLO is discussed

(30d)
r/wallstreetbets 40% 2 +0.05
r/ausfinance 20% 1 +0.12
r/commodities 20% 1 +0.34
r/etfs 20% 1 +0.14

Allogene Therapeutics (ALLO) insider trades

SEC Form 4 · last 90 days · newest reported trade 21 Oct 2026

In the 90 days to 26 Oct 2026, Allogene Therapeutics insiders reported 2 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 21 Oct 2025, show no open-market purchase.

Open-market buys 0
Open-market sells 2
Net sold $112K
Non-trade filings 0
Date Insider Type Shares Value
21 Oct 2026 Parker Geoffrey M. CHIEF FINANCIAL OFFICER Sell 36,342 $49K
21 Aug 2026 Douglas Earl Martin SVP, General Counsel Sell 29,697 $63K

Allogene Therapeutics (ALLO) reported financials

SEC EDGAR XBRL SEC EDGAR

Allogene Therapeutics reported revenue of $0 for the fiscal year ended 31 Dec 2025. Net income over the same period was −$190.9M.

Figure Reported Period
Revenue $0 31 Dec 2025 fiscal year
Net income −$190.9M 31 Dec 2025 fiscal year
Diluted EPS −$0.87 31 Dec 2025 fiscal year
Total assets $550.1M 30 Jun 2026 at period end
Total equity $436.2M 30 Jun 2026 at period end

Allogene Therapeutics (ALLO) earnings

SEC EDGAR

Allogene Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$0.13; no next date is announced in SEC filings yet.

Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$0.13 $5M
31 Mar 2026 Q1 2026 −$0.18 —
31 Dec 2025 FY 2025 −$0.87 —
30 Sep 2025 Q3 2025 −$0.19 —
30 Jun 2025 Q2 2025 −$0.23 —
31 Mar 2025 Q1 2025 −$0.28 —
31 Dec 2024 FY 2024 −$1.32 $0M
30 Sep 2024 Q3 2024 −$0.32 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

Allogene Therapeutics (ALLO) institutional holders (13F)

SEC Form 13F SEC EDGAR

8 of the 45 institutional funds we track reported a Allogene Therapeutics position for the quarter ended 30 Jun 2026 — a combined $81.3M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Citadel Advisors Added +48.5% shares 10,087,770 $21.0M
Two Sigma Investments Added +44.8% shares 7,784,348 $16.2M
Marshall Wace Added +47.8% shares 5,095,408 $10.6M
Millennium Management Added +45.8% shares 4,843,889 $10.1M
D. E. Shaw & Co. Added +70.4% shares 4,710,735 $9.8M
Renaissance Technologies Added +79.2% shares 3,834,312 $8.0M
AQR Capital Management Held (±25%) −19.3% shares 2,006,288 $4.2M
Man Group Added +353.8% shares 701,901 $1.5M
Balyasny Asset Management Exited
Point72 Asset Management Exited

Allogene Therapeutics (ALLO) fails-to-deliver

SEC CNS data SEC

On 29 Sep 2026, 6,505,279 shares of Allogene Therapeutics failed to deliver (about $10.6M) — the latest of 3 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
29 Sep 2026 6,505,279 $10.6M 1.883%
28 Sep 2026 34,042 $56K 0.010%
25 Sep 2026 1,892 $3K 0.001%
17 Sep 2026 14,248 $24K 0.004%
16 Sep 2026 1,838 $3K 0.001%

Allogene Therapeutics (ALLO): frequently asked questions

From live data

Have Allogene Therapeutics insiders bought or sold shares recently?

In the 90 days to 26 Oct 2026, Allogene Therapeutics insiders reported 2 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 21 Oct 2025, show no open-market purchase.

How many institutions hold Allogene Therapeutics?

8 of the 45 institutional funds we track reported a Allogene Therapeutics position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Allogene Therapeutics had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Allogene Therapeutics is dated 29 Sep 2026, when 6,505,279 shares failed to deliver.

When did Allogene Therapeutics last report earnings?

Allogene Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$0.13; no next date is announced in SEC filings yet.

What exchange is Allogene Therapeutics listed on?

Allogene Therapeutics trades on NASDAQ under the ticker ALLO.

What is Reddit saying about Allogene Therapeutics?

Allogene Therapeutics was mentioned 1 times in the last 7 days across the finance subreddits we track, and 5 times over the trailing 30 days. Of 5 classified mentions, 80% read bullish, 0% bearish and 20% neutral. Crowd sentiment is a social signal, not investment advice.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. RedditReddit ingest across the tracked finance subreddits
  4. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  5. SEC EDGARSEC EDGAR 13F filings
  6. SECSEC fails-to-deliver (CNS) data
  7. SEC EDGARValuation computed from SEC EDGAR filings